Lauffenburger:Laura Sontag: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
 
mNo edit summary
Line 6: Line 6:
[[Image:Laura_Sontag.JPG|150px|right]]
[[Image:Laura_Sontag.JPG|150px|right]]


'''Laura Sontag''' (CSB doctoral), in collaboration with Prof. Peter Sorger
'''Laura Sontag''' (Computational and Systems Biology doctoral student), in collaboration with Prof. Peter Sorger (Biology/BE, MIT) and Prof. Tyler Jacks (Biology/Center for Cancer Research,
(Biology/BE, MIT) and Prof. Tyler Jacks (Biology/Center for Cancer Research,
MIT)
MIT)


Computational and experimental analysis of mitogenic signaling pathways
Computational and experimental analysis of mitogenic signaling pathways
activated by a mutation in the K-ras oncogene.  The Ras signaling cascade
activated by mutations in the K-ras oncogene.  The Ras signaling cascade
constitutes a major pathway shown to be misregulated due to activating
constitutes a major pathway shown to be deregulated due to activating
mutations in 30% of all human tumors.  The vast majority of mutations occur in
mutations in 30% of all human tumors.  The vast majority of mutations occur in the
K-ras.  We use genetically engineered mice that harbor a conditional,
K-ras isoform.  We use genetically engineered mice that harbor a conditional,
activatable allele of the K-ras oncogene as a model of human cancer.
activatable K-ras allele as a model of human cancer.
 
 
Email:  sontag {AT} mit {DOT} edu


[http://www.mit.edu/~sontag/ Laura Sontag's Homepage]


</div>
</div>
|}
|}

Revision as of 14:46, 6 January 2006

Home        People        Research        Publications        Links        Internal       

Laura Sontag (Computational and Systems Biology doctoral student), in collaboration with Prof. Peter Sorger (Biology/BE, MIT) and Prof. Tyler Jacks (Biology/Center for Cancer Research, MIT)


Computational and experimental analysis of mitogenic signaling pathways activated by mutations in the K-ras oncogene. The Ras signaling cascade constitutes a major pathway shown to be deregulated due to activating mutations in 30% of all human tumors. The vast majority of mutations occur in the K-ras isoform. We use genetically engineered mice that harbor a conditional, activatable K-ras allele as a model of human cancer.


Email: sontag {AT} mit {DOT} edu

Laura Sontag's Homepage